ESR2 and Hepatic fibrosis: ERβ activation has also been implicated in reducing hepatic fibrosis in vivo in a carbon tetrachloride rat model of cirrhosis; treatment with a selective ERβ antagonist (and not selective ERα or GPER1 antagonists) abolished the beneficial effect of E2 on liver fibrosis scores (29).